[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"SSC- Surgical Specialties Corporation\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":92},{"warningLetters":4,"total":91},[5,31,53,70],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},898,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-05-20T04:00:00Z\">05\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-05-08T04:00:00Z\">05\u002F08\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrospecialties-llc-707614-05082025\">Microspecialties, LLC\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gaston S. Levesque\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Microspecialties, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>430 Smith Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Middletown\u003C\u002Fspan>, \u003Cspan>CT\u003C\u002Fspan> \u003Cspan>06457\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:steven.levesque@microspecialties.com\"> steven.levesque@microspecialties.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 707614\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 8, 2025\u003C\u002Fp>\u003Cp>Dear Gaston S. Levesque:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Middletown, CT, from January 14, 2025, through February 18, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm contract manufactures Class I and II ophthalmic surgical devices such as sterile I-PACK injection kits, punctum plugs, and microkeratome blades. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Rick Brinsmade, Quality Assurance and Regulatory Affairs (QA\u002FRA) Manager, dated March 4, 2025 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR 820.80(d).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 6.13 of your “Sterilization Process Control” procedure (QA-0041; Rev 3; Effective: 1\u002F27\u002F23) which requires release of sterile products to inventory via Form 0070 once accompanying dosimetry records and certificates of processing (COPs) are received back from the contract sterilizer. For example, you stated that Form 0070 was never utilized to release \u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes of I-PACK injection kits (Lot #: P62764979R, P63044983R, P62764965R and P62764970R) into inventory because you fabricated the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization COPs (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) as if they originated from the customer-approved contract sterilizer. Subsequently, on 03\u002F21\u002F24, your Director of Quality Assurance released the above nonconforming lots of I-PACK injection kits, which are intended for administration of intravitreal injections during eye surgery, as sterile to your customer on 3\u002F12\u002F24 despite never shipping these products to the customer-approved contract sterilizer (or elsewhere) for sterilization. This event resulted in a Class II recall RES 94794 initiated by your firm on 6\u002F5\u002F24 followed up by a Class I recall by your customer on \u003Cstrong>(b)(4)\u003C\u002Fstrong> under RES \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The adequacy of the response dated 3\u002F4\u002F25 cannot be determined at this time. Under CAR # 1288 (2\u002F20\u002F25) opened to address the failure to follow QA-0041, you reference CAR # 1261 (5\u002F31\u002F24) for the root cause which pointed to limited resources, lack of effectiveness of training, storage of product in a non-routine location, and lack of \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization labels. Corrective actions included notification of the nonconforming lots to your customer upon discovery of the error; replacement of your Director of Quality Assurance with a new Quality Assurance and Regulatory Affairs Manager; addition of \u003Cstrong>(b)(4)\u003C\u002Fstrong> exposure indication dots to shipping cartons; update of Form 0070 to include verification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> indicator dot color changes; update of QA-0041 to restrict product release to QA, President, or Administrative Assistant; update the training procedure (QA-0019) to include effectiveness tests, including a test for sterilization processes; and retrospective review of sterilization and release documentations to verify accuracy. Under CAR # 1289 (2\u002F20\u002F25) opened to address release of nonconforming product, you also reference the root cause(s) and several of the corrective actions above under CAR # 1261 and note additional completed actions which included the requirement for \u003Cstrong>(b)(4)\u003C\u002Fstrong> irradiation exposure dots on shipping cartons and process specifications for your new contract sterilizer in QA-0041; addition of integrity requirements to the document, part number, and data control procedure (QA-0020); and a new code of conduct and ethics procedure (QA-0099) for which all employees completed training. By 6\u002F1\u002F25, you plan to also add irradiation exposure dots to each individual carton of trays and microkeratome blades. Please provide updates on the progress of these corrective actions and corrections, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically:\u003C\u002Fp>\u003Cp>a. You failed to implement sections 5.1.2 and 5.2.1 of your “Process Validation” procedure (QA-0063; Effective: 11\u002F8\u002F23) which requires that Operations (with input from Quality) determine “***\u003Cem>if re-validation is needed for changes to validation manufacturing processes\u003C\u002Fem>***” and that Quality “***\u003Cem>Reviews and approves the assessments of validation needs and revalidation determinations\u003C\u002Fem>***,” respectively. For example, you authorized the release of lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 9\u002F4\u002F24; \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 10\u002F14\u002F24; and \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 11\u002F19\u002F24, containing medical devices, such as punctum plugs, customized injection trays, microkeratome blades, microkeratome tubing, and ophthalmic convenience kits, for distribution without documented justification for why a revalidation was not required, prior to switching to a new contract sterilizer for \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization of such devices on 3\u002F19\u002F24.\u003C\u002Fp>\u003Cp>b. You failed to implement sections 1.0 and 2.0 of your “Process Validation” procedure (QA-0063; Effective: 11\u002F8\u002F23) which require validations of processes related to inventory items such as “***\u003Cem>a component, material, assembly, packaging, and labeling that is part or will become part of the finished medical device including the finished medical device\u003C\u002Fem>***.” For example, you did not conduct a validation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection method outlined in section 6.1.2 of the “Seal Inspection” procedure (QA-0042; Effective: 6\u002F30\u002F24) for testing the seal integrity of sterile pouches containing Microkeratome Blades, to ensure that manufacturing employees are able to repeatably and reproducibly able to detect conforming and nonconforming seal pouches with a high degree of assurance as a part of finished device acceptance. These devices are indicated for use during LASIK surgery to shave tissue from sections of the cornea for a lamellar (partial thickness) transplant.\u003C\u002Fp>\u003Cp>The response dated 3\u002F4\u002F25 is not adequate. Under CAR # 1290 (2\u002F20\u002F25) initiated to address release of sterile products prior to conducting a revalidation for the new contract sterilizer, you state that management did not believe that a revalidation was required because the new contract \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilizer was able to sterilize the product with the specified dose mapping and dose audits and bioburden testing continued. In addition, you point out that your newly hired QA\u002FRA manager determined that a retrospective validation was required such that a comprehensive validation was conducted and formally approved on 12\u002F16\u002F24. However, there were no corrective actions identified to address the primary issue which is that you did not follow your procedure to review and approve your decision not to revalidate the sterilization process at the time these products were released for distribution.\u003C\u002Fp>\u003Cp>With regards to the lack of test method validation for the seal integrity inspection, you state that you will write a formal process adoption by analyzing the data outputs from the seal validations by 5\u002F1\u002F25. However, there were no corrective actions identified to review whether any other test methods require process validations to demonstrate that that you are able to consistently detect conforming and nonconforming product with a high degree of assurance. Therefore, please provide a response on how you plan to address the above deficiencies.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to ensure that sampling plans are written and based on a valid statistical rationale when used, as required by 820.250(b).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you acknowledged there was no statistical rationale documented for the sampling plan in section 6.1.2 of the “Seal Inspection” procedure (QA-0042; Effective: 6\u002F30\u002F24) to inspect the first \u003Cstrong>(b)(4)\u003C\u002Fstrong> pouches for seal integrity.\u003C\u002Fp>\u003Cp>The response dated 3\u002F4\u002F25 is not adequate. Under CAR # 1290 (2\u002F20\u002F25) initiated to address the lack of test method validation for the seal integrity inspection as well as failure to provide statistically supported evidence when sampling, you state that you will write a formal process adoption by analyzing the data outputs from the seal validations by 5\u002F1\u002F25. However, there were no corrective actions identified to address the concerns relating to lack of valid statistical rationale for the sampling plan employed during sealing inspections of sterile pouches. Therefore, please provide a response on how you plan to address the above deficiencies.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 707614” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Rick Brinsmade, QA\u002FRA Manager, rick@pro-paks.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nGaston S. Levesque\n\nRecipient Title\n\nPresident and CEO\n\nMicrospecialties, LLC\n\n430 Smith Street\n\nMiddletown, CT 06457\n\nUnited States\n\nsteven.levesque@microspecialties.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 707614\nMay 8, 2025\nDear Gaston S. Levesque:\nDuring an inspection of your firm located in Middletown, CT, from January 14, 2025, through February 18, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm contract manufactures Class I and II ophthalmic surgical devices such as sterile I-PACK injection kits, punctum plugs, and microkeratome blades. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Rick Brinsmade, Quality Assurance and Regulatory Affairs (QA\u002FRA) Manager, dated March 4, 2025 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR 820.80(d).\nSpecifically, you failed to implement section 6.13 of your “Sterilization Process Control” procedure (QA-0041; Rev 3; Effective: 1\u002F27\u002F23) which requires release of sterile products to inventory via Form 0070 once accompanying dosimetry records and certificates of processing (COPs) are received back from the contract sterilizer. For example, you stated that Form 0070 was never utilized to release (b)(4) boxes of I-PACK injection kits (Lot #: P62764979R, P63044983R, P62764965R and P62764970R) into inventory because you fabricated the (b)(4) sterilization COPs ((b)(4) and (b)(4)) as if they originated from the customer-approved contract sterilizer. Subsequently, on 03\u002F21\u002F24, your Director of Quality Assurance released the above nonconforming lots of I-PACK injection kits, which are intended for administration of intravitreal injections during eye surgery, as sterile to your customer on 3\u002F12\u002F24 despite never shipping these products to the customer-approved contract sterilizer (or elsewhere) for sterilization. This event resulted in a Class II recall RES 94794 initiated by your firm on 6\u002F5\u002F24 followed up by a Class I recall by your customer on (b)(4) under RES (b)(4).\nThe adequacy of the response dated 3\u002F4\u002F25 cannot be determined at this time. Under CAR # 1288 (2\u002F20\u002F25) opened to address the failure to follow QA-0041, you reference CAR # 1261 (5\u002F31\u002F24) for the root cause which pointed to limited resources, lack of effectiveness of training, storage of product in a non-routine location, and lack of (b)(4) sterilization labels. Corrective actions included notification of the nonconforming lots to your customer upon discovery of the error; replacement of your Director of Quality Assurance with a new Quality Assurance and Regulatory Affairs Manager; addition of (b)(4) exposure indication dots to shipping cartons; update of Form 0070 to include verification of (b)(4) indicator dot color changes; update of QA-0041 to restrict product release to QA, President, or Administrative Assistant; update the training procedure (QA-0019) to include effectiveness tests, including a test for sterilization processes; and retrospective review of sterilization and release documentations to verify accuracy. Under CAR # 1289 (2\u002F20\u002F25) opened to address release of nonconforming product, you also reference the root cause(s) and several of the corrective actions above under CAR # 1261 and note additional completed actions which included the requirement for (b)(4) irradiation exposure dots on shipping cartons and process specifications for your new contract sterilizer in QA-0041; addition of integrity requirements to the document, part number, and data control procedure (QA-0020); and a new code of conduct and ethics procedure (QA-0099) for which all employees completed training. By 6\u002F1\u002F25, you plan to also add irradiation exposure dots to each individual carton of trays and microkeratome blades. Please provide updates on the progress of these corrective actions and corrections, including any supporting evidence.\n2. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\nSpecifically:\na. You failed to implement sections 5.1.2 and 5.2.1 of your “Process Validation” procedure (QA-0063; Effective: 11\u002F8\u002F23) which requires that Operations (with input from Quality) determine “***if re-validation is needed for changes to validation manufacturing processes***” and that Quality “***Reviews and approves the assessments of validation needs and revalidation determinations***,” respectively. For example, you authorized the release of lots (b)(4) on 9\u002F4\u002F24; (b)(4) on 10\u002F14\u002F24; and (b)(4) on 11\u002F19\u002F24, containing medical devices, such as punctum plugs, customized injection trays, microkeratome blades, microkeratome tubing, and ophthalmic convenience kits, for distribution without documented justification for why a revalidation was not required, prior to switching to a new contract sterilizer for (b)(4) sterilization of such devices on 3\u002F19\u002F24.\nb. You failed to implement sections 1.0 and 2.0 of your “Process Validation” procedure (QA-0063; Effective: 11\u002F8\u002F23) which require validations of processes related to inventory items such as “***a component, material, assembly, packaging, and labeling that is part or will become part of the finished medical device including the finished medical device***.” For example, you did not conduct a validation of the (b)(4) inspection method outlined in section 6.1.2 of the “Seal Inspection” procedure (QA-0042; Effective: 6\u002F30\u002F24) for testing the seal integrity of sterile pouches containing Microkeratome Blades, to ensure that manufacturing employees are able to repeatably and reproducibly able to detect conforming and nonconforming seal pouches with a high degree of assurance as a part of finished device acceptance. These devices are indicated for use during LASIK surgery to shave tissue from sections of the cornea for a lamellar (partial thickness) transplant.\nThe response dated 3\u002F4\u002F25 is not adequate. Under CAR # 1290 (2\u002F20\u002F25) initiated to address release of sterile products prior to conducting a revalidation for the new contract sterilizer, you state that management did not believe that a revalidation was required because the new contract (b)(4) sterilizer was able to sterilize the product with the specified dose mapping and dose audits and bioburden testing continued. In addition, you point out that your newly hired QA\u002FRA manager determined that a retrospective validation was required such that a comprehensive validation was conducted and formally approved on 12\u002F16\u002F24. However, there were no corrective actions identified to address the primary issue which is that you did not follow your procedure to review and approve your decision not to revalidate the sterilization process at the time these products were released for distribution.\nWith regards to the lack of test method validation for the seal integrity inspection, you state that you will write a formal process adoption by analyzing the data outputs from the seal validations by 5\u002F1\u002F25. However, there were no corrective actions identified to review whether any other test methods require process validations to demonstrate that that you are able to consistently detect conforming and nonconforming product with a high degree of assurance. Therefore, please provide a response on how you plan to address the above deficiencies.\n3. Failure to ensure that sampling plans are written and based on a valid statistical rationale when used, as required by 820.250(b).\nSpecifically, you acknowledged there was no statistical rationale documented for the sampling plan in section 6.1.2 of the “Seal Inspection” procedure (QA-0042; Effective: 6\u002F30\u002F24) to inspect the first (b)(4) pouches for seal integrity.\nThe response dated 3\u002F4\u002F25 is not adequate. Under CAR # 1290 (2\u002F20\u002F25) initiated to address the lack of test method validation for the seal integrity inspection as well as failure to provide statistically supported evidence when sampling, you state that you will write a formal process adoption by analyzing the data outputs from the seal validations by 5\u002F1\u002F25. However, there were no corrective actions identified to address the concerns relating to lack of valid statistical rationale for the sampling plan employed during sealing inspections of sterile pouches. Therefore, please provide a response on how you plan to address the above deficiencies.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 707614” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Rick Brinsmade, QA\u002FRA Manager, rick@pro-paks.com","Microspecialties, LLC","microspecialties-llc-707614-05082025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrospecialties-llc-707614-05082025","2026-10-26T08:09:24.836404+00:00","Warning Letter","Issued","2025-05-20","707614","Medical Devices","Gaston S. Levesque","2026-08-19T16:46:07.915+00:00","VIA Electronic Mail","2025-05-08",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},1096,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2025-01-14T14:20:00Z\">01\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-23T05:00:00Z\">12\u002F23\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgeorge-food-specialties-inc-697738-12232024\">By George Food Specialties Inc.\u003C\u002Fa>","Division of Northern Border Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Susan L. Walsh\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>By George Food Specialties Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1149 State Route 50\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ballston Lake\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>12019-1922\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northern Border Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 23, 2024\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS # 697738\u003C\u002Fp>\u003Cp>Dear Ms. Walsh:\u003C\u002Fp>\u003Cp>On 11\u002F4\u002F2024-11\u002F25\u002F2024, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of By George Food Specialties Inc. located at 1149 State Route 50. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on 11\u002F25\u002F2024.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import. Including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>Mayonnaise imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Mayonnaise imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Hot Sauce imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>\u003C\u002Fp>\u003Cp>In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Alyssa Wenke, Compliance Officer, Division of Northern Border Imports. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Alyssa Wenke via email at Alyssa.Wenke@fda.hhs.gov. Please reference CMS # 697738 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Keith J. Jasukaitis\u003Cbr>Program Division Director\u003Cbr>Division of Northern Border Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMs. Susan L. Walsh\n\nBy George Food Specialties Inc.\n\n1149 State Route 50\n\nBallston Lake, NY 12019-1922\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nDivision of Northern Border Imports\n\nUnited States\n\nDecember 23, 2024\nWARNING LETTER\nRe: CMS # 697738\nDear Ms. Walsh:\nOn 11\u002F4\u002F2024-11\u002F25\u002F2024, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of By George Food Specialties Inc. located at 1149 State Route 50. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on 11\u002F25\u002F2024.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import. Including each of the following foods:\nMayonnaise imported from (b)(4) located in (b)(4)\nMayonnaise imported from (b)(4) located in (b)(4)\nHot Sauce imported from (b)(4) located in (b)(4)\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\nIn addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Alyssa Wenke, Compliance Officer, Division of Northern Border Imports. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Alyssa Wenke via email at Alyssa.Wenke@fda.hhs.gov. Please reference CMS # 697738 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nKeith J. Jasukaitis\nProgram Division Director\nDivision of Northern Border Imports","By George Food Specialties Inc.","george-food-specialties-inc-697738-12232024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgeorge-food-specialties-inc-697738-12232024","2026-10-26T08:08:45.641765+00:00","2025-01-14","697738","Food & Beverages","Ms. Susan L. Walsh","2026-08-19T17:04:39.444+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2024-12-23",{"id":54,"raw":55,"subject":12,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":18,"fei_number":19,"letter_url":63,"updated_at":64,"action_type":22,"case_status":23,"posted_date":65,"marcs_cms_no":66,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":67,"body_fetched_at":68,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":69,"medical_device_id":19,"response_letter_date":19},746,[56,57,58,11,12,13,13,13],"\u003Ctime datetime=\"2025-07-29T04:00:00Z\">07\u002F29\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-21T04:00:00Z\">07\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fonkos-surgical-inc-712573-07212025\">Onkos Surgical, Inc. \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Patrick J. Treacy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Onkos Surgical, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>77 E Halsey Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Parsippany\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07054\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ptreacy@onkossurgical.com\"> ptreacy@onkossurgical.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 712573\u003C\u002Fp>\u003Cp>July 21, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Patrick J. Treacy:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Parsippany, NJ from February 4, 2025 through April 4, 2025, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer of the ELEOS Limb Salvage System indicated for use in total hip and knee arthroplasty for reduction or relief of pain and\u002For improved hip function in skeletally mature patients with select conditions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Len Tokish, Vice President of Quality Assurance and Regulatory Affairs dated May 15, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including quality requirements, that must be met by suppliers, contractors, and consultants and define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to adequately implement the “Approved Supplier List” section of your “Supplier, Purchasing and Inspection Controls” procedure (SOP-013; Rev. 0-6; Effective: 4\u002F25\u002F16 - 2\u002F3\u002F25) which requires that you “\u003Cem>ensure compliance to ISO 13485\u003C\u002Fem>” for your Tier 1 suppliers as a “method of control” over approved suppliers. For example, you did not ensure compliance to the process validation requirements (clause 7.5.6) of ISO 13485 (Medical Devices – Quality Management Systems – Requirements for regulatory purposes) for the following three (3) Tier 1 suppliers in that you failed to adequately assess and\u002For document an assessment of the acceptability of their cleaning validations meant to demonstrate that in-process or final cleaning of your ELEOS Implant Devices and Instruments consistently meet your specifications for cleanliness:\u003C\u002Fp>\u003Cp>a. \u003Cstrong>(b)(4)\u003C\u002Fstrong> – Tier \u003Cstrong>(b)(4)\u003C\u002Fstrong> Final Cleaner of ELEOS Implant Devices\u003C\u002Fp>\u003Cp>i. You approved the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validation test report TR-2771D-01 (Rev. 1-2; Approved: 1\u002F24\u002F19 and 9\u002F10\u002F21) from this supplier despite it failing to define the maximum allowable devices per gallon per run, as required by section 9.2 of the corresponding test protocol TP-2771D-01 (Rev. 2; Approved: 9\u002F10\u002F21) which states “***\u003Cem>The main cleaning parameters that can impact the efficacy of the cleaning process include ***Quantity of parts\u003C\u002Fem> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)***.”\u003C\u002Fp>\u003Cp>Similarly, you approved \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validation test report TR-2771E-01 (Rev. 1; Approved: 3\u002F18\u002F19) from this supplier despite it failing to document the maximum allowable quantity of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> per run, as required by sections 9.3, 9.4, and 9.5 of the corresponding test protocol TP-2771E-01 (Rev. 1; Approved: 8\u002F28\u002F18) which state “***\u003Cem>To validate the cleaning process, parts shall be cleaned using\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>over\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>runs***To create a\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>batch of product***Clean what is expected to be a\u003C\u002Fem> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” load in \u003Cstrong>(b)(4)\u003C\u002Fstrong>***\u003Cem>A cleaning process should not alter the appearance of parts or cause damage. If applicable, appropriate fixtures to hold the components during cleaning should be included in the study and used in routine production\u003C\u002Fem>***.”\u003C\u002Fp>\u003Cp>ii. You failed to adequately assess differences in product design and geometrical configurations of candidate devices for the adoption into device families of existing \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validations conducted by this supplier because you did not accurately answer guiding questions contained in your “\u003Cem>Assessment of Product Change or New Product Adoption for Cleaning Processes\u003C\u002Fem>” reports. For example:\u003C\u002Fp>\u003Cp> The AC-2772-01 (Rev. 01; Effective: 7\u002F25\u002F19) and AC-277D-01 (Rev. 2; Effective: 2\u002F26\u002F21) reports show that you failed to document rationale to support your answers of “no” to the question posed in section 2 – “\u003Cem>In relation to the existing product, does the candidate product have a similar or less complex design?\u003C\u002Fem>” – despite the candidate devices having 4 grooves, a drive, or a male thread compared to the worst-case and comparison devices, which have none of these features.\u003C\u002Fp>\u003Cp> The AC-2772-02 report (Rev. 1; Effective: 3\u002F23\u002F20) shows that you incorrectly answered “no” to the question posed in section 2 – “\u003Cem>In relation to the existing product, does the candidate product have fewer\u002Fsmaller or equivalent cannulated portions or lumens?\u003C\u002Fem>” – when you compared the candidate device (segmental proximal femur, PF-2000L-02M), which has 7 cannulated holes, to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> device (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) and comparison devices (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), which contain no holes.\u003C\u002Fp>\u003Cp>b. \u003Cstrong>(b)(4)\u003C\u002Fstrong> – Tier 1 \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaner of ELEOS Implant Devices\u003C\u002Fp>\u003Cp>Although requested during the inspection, your Vice President of Quality Affairs and Regulatory Affairs was unable to provide documentation that you assessed the adequacy of the cleaning validations conducted in 2009 by this supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In reviewing the “Process Validation of***\u003Cstrong>(b)(4)\u003C\u002Fstrong> Clean Line” Operational Qualification (OQ) (E118-2116; Rev. 1; Approved: 1\u002F9\u002F09) and Performance Qualification (PQ) (E118-2116; Rev. 1; Approved: 2\u002F3\u002F09), the following deficiencies were observed:\u003C\u002Fp>\u003Cp>i. The rationale in the PQ report to accept deviations from the nominal operating range of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F) because OQ data showed that the process monitoring, total organic carbon (TOC), and gravimetric produced acceptable results at worst-case conditions for temperatures as low as \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F and control charts indicated a lower control limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (Deviation 3) does not take into account the vast differences in sample sizes (\u003Cstrong>(b)(4)\u003C\u002Fstrong> vs. \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and acceptance criterion (Ppk \u003Cstrong>(b)(4)\u003C\u002Fstrong> vs. Ppk \u003Cstrong>(b)(4)\u003C\u002Fstrong>) between PQ and OQ for the same tests (TOC and gravimetric analysis) such that passing results for parameters established during OQ are not transferrable to PQ.\u003C\u002Fp>\u003Cp>ii. This supplier failed to document rationale in the OQ and PQ reports for why it was acceptable to convert all negative values measured for the corrected “\u003Cem>mass recovered from gravimetric\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> and corrected “\u003Cem>mass recovered from\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> to 0.00 mg in the “\u003Cem>Gravimetric Extraction Summary\u003C\u002Fem>” table during gravimetric testing, thereby passing the acceptance criteria of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002Fcm\u003Csup>2\u003C\u002Fsup> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). For example, during OQ, an \u003Cstrong>(b)(4)\u003C\u002Fstrong> value as high as -1.59 mg for “Hip – 4” was converted to 0.00 mg without an explanation that accounts for the possibility of testing errors, inadequate test methodology (e.g., lack of sensitivity of testing methods), and uncalibrated state of measuring equipment.\u003C\u002Fp>\u003Cp>c. \u003Cstrong>(b)(4)\u003C\u002Fstrong> – \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaner of ELEOS Implant Devices &amp; \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaner of ELEOS Instruments\u003C\u002Fp>\u003Cp>You approved the adoption of new products into this supplier’s existing \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validations titled “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Equipment &amp; Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) and “Zenith Final Ultrasonic Cleaning Equipment &amp; Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) per your Cleaning, Assembly, Packaging and Sterility (CAPS) Checklists for Project # 16-001 (Approved 10\u002F2\u002F24) and Project # 16-003 (Approved 4\u002F19\u002F24) referencing memo “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning” (2\u002F14\u002F19) and results of a 3rd party audit conducted 2\u002F23\u002F18 despite the following deficiencies:\u003C\u002Fp>\u003Cp>i. The OQ and PQ protocols failed to require documentation of the load configurations for all work orders in that the Vice President of Quality Affairs and Regulatory Affairs was not able to determine if devices were put in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> or broken up into \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>ii. The PQ protocol failed to include documentation of valid statistical rationale for cytotoxicity, endotoxin, and\u002For particulate testing. For example, the quantity tested per work order (66672, 66921, 66922) for cytotoxicity and endotoxin was \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> respectively and the quantity tested per work order (66675, 66919, 66920) for cytotoxicity, endotoxin, and particulate was \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The immediate correction is to impose heightened controls at each supplier commensurate with risk until new worst-case cleaning validations can be completed that addresses each of the observed deficiencies for \u003Cstrong>(b)(4)\u003C\u002Fstrong> by 1\u002F15\u002F26, \u003Cstrong>(b)(4)\u003C\u002Fstrong> (target date not provided), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> by 3\u002F1\u002F26 at the latest.\u003C\u002Fp>\u003Cp>For \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an assessment of worst-case part justification by family was completed to establish new limits placed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You plan to add this new loading criteria to the final DHR review by 7\u002F15\u002F25. In addition, you plan to require an update to \u003Cstrong>(b)(4)\u003C\u002Fstrong> internal procedure to include predicate cleaning validation review by 7\u002F15\u002F25. Based on the results of the new cleaning validation, you plan to revise top level procedures by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>For \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an assessment of worst-case part justification was conducted and monitoring was put in place to control product release by assessing endotoxicity and cytotoxicity on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis. In addition, you plan to require an update to this supplier’s internal procedures to improve notification of triggers to their customers by 7\u002F1\u002F25.\u003C\u002Fp>\u003Cp>For \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you plan to conduct an assessment for worst-case part challenge per part family by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For all instruments, interim clean line controls were implemented to require shipment of instruments to your firm and analyses of those instruments, which includes worst-case part and part family assessments prior to adoption into your clean-line part family. All parts successfully assessed will then be cleaned using your validated clean line prior to release for commercial distribution. All implants will continue to be shipped to \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning and will fall under controls established for therein.\u003C\u002Fp>\u003Cp>Corrective actions include updating your supplier control and design control procedures to establish minimum requirements for cleaning validations of implants and instruments, including defining key product attributes to consider when forming product families and what considerations trigger a new worst-case within a product family or new product cleaning family; creation of a procedure for part families and worst-case parts per family which defines and evaluates implant and instrument cleaning families to facilitate consistent assessment of device cleaning families across products; determination and justification of minimum sample size and attributes (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) for validations; development of a cleaning validation checklist and modification of a supplier audit checklist that captures the aforementioned worst-case part determination, sample sizes, and minimum attributes that will be used during supplier assessment as part of design transfer and new supplier onboarding, manufacturing transfer, and supplier audit; and periodic review of validations on a scheduled interval against new standards and requirements by 6\u002F15\u002F25.\u003C\u002Fp>\u003Cp>However, no target date was provided for the new cleaning validation planned for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, please provide a response regarding how you plan to address this deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement your Post Market Surveillance procedure (QP-18-004; Rev. 3; Effective: 6\u002F30\u002F22) which requires opening a CAPA when the \u003Cstrong>(b)(4)\u003C\u002Fstrong> analysis of infection complaints “***\u003Cem>is more than\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>above the literature rate or\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>are above the literature rate\u003C\u002Fem>***” for a given procedure type. For example, you did not initiate CAPAs when the \u003Cstrong>(b)(4)\u003C\u002Fstrong> analysis for infection complaints exceeded the rates of \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for the distal femur (\u003Cstrong>(b)(4)\u003C\u002Fstrong>); \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for proximal femur (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>); and \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for total femur (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) established in the journal article by Henderson et. al “\u003Cem>Failure Mode Classification for Tumor Endoprostheses: Retrospective Review of Five Institutions and a Literature Review\u003C\u002Fem>” (Journal Bone and Joint Surgery 2011) by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. Under CAPA 24-011 which was initiated on 9\u002F11\u002F24 to create a more robust methodology for trending and analyzing infection related complaints, you conducted a revised retrospective assessment of \u003Cstrong>(b)(4)\u003C\u002Fstrong> infection rates from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> (TM-25-0002; Rev. B; Approved 5\u002F14\u002F25) based on additional literature data to support updated baseline infection rates by procedure type. As a part of the corrective action, you plan to create new work instructions with requirements to perform \u003Cstrong>(b)(4)\u003C\u002Fstrong> trend reporting for infections and \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> trend reports for all other postmarket surveillance key performance indicators (KPIs); revise management review presentation slides and quality planning, postmarket surveillance, complaint handling, and CAPA procedures; and provide training on the new procedures. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to adequately establish and maintain procedures for validating the device design with regards to risk analysis, as required by 21 CFR 820.30(g).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 5.9 of your “Risk Management Process” procedure (SOP-008; Rev. 4-5; Effective: 3\u002F22\u002F23 - 1\u002F17\u002F25) which requires postmarket re-evaluation of risk management for a medical device as well as monitoring of postmarket information “***\u003Cem>for assurance that no unacceptable or previously unrecognized failure modes occur. In the event of such an occurrence the potential that the residual risk or its acceptability has changed and the impact on the previously implemented risk control measures shall be evaluated\u003C\u002Fem>***.” For example, you failed to utilize the real rate of occurrence for loosening in complaints PCR 11272023-1 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), PCR 05132024-1 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), and PCR 10172024-1 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) calculated at 3.27%, 0.149%, and 3.1%, respectively, to evaluate the need to update the occurrence rating in the corresponding ELEOS Stem Implant Risk Table (Project # 16-001\u002F16-003; Rev. E; Approved: 4\u002F1\u002F19), which remains unchanged at \u003Cstrong>(b)(4)\u003C\u002Fstrong>% through \u003Cstrong>(b)(4)\u003C\u002Fstrong>% since April 1, 2019.\u003C\u002Fp>\u003Cp>An update to the postmarket rate of occurrence changes the failure mode from an acceptable risk to a conditionally acceptable risk, thereby requiring an evaluation for the need for additional risk controls and assessment for the acceptability of the residual risk as required under sections 5.6 and 5.7 of SOP-008.\u003C\u002Fp>\u003Cp>The adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. The immediate correction is to evaluate literature, sources, historical data, and\u002For engineering estimates against postmarket data and update the occurrence rates for the hazardous situations associated with the ELEOS Limb Salvage system by \u003Cstrong>(b)(4)\u003C\u002Fstrong> followed by a revision of the corresponding risk tables by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. As a part of the corrective action, you plan to revise SOP-008 to ensure that the methods used to create and maintain risk assessment tables are well-defined and create work instructions for conducting risk assessments utilizing postmarket information by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to establish and maintain procedures for identifying valid statistical techniques required for establishing, controlling, and verifying the acceptability of process capability and product characteristics, as required by 21 CFR 820.250(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 1.1 of your “Sample Size and Statistical Techniques” procedure (SOP-014; Rev. 2-4; Effective: 8\u002F16\u002F18 - 3\u002F22\u002F23) which “***\u003Cem>identifies valid statistical techniques that are used to establish, control and verify the acceptability of process capability and product characteristics***” pertaining to “***inspections and other analyses of objective data\u003C\u002Fem>***” of ELEOS Implant Devices received from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. during incoming inspections. For example, your Vice President of Quality Affairs and Regulatory Affairs acknowledged that the sampling plans of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampled incoming device history records (DHRs) from this supplier were not traceable to a documented valid statistical rationale.\u003C\u002Fp>\u003Cp>a. You reviewed and approved incoming DHRs for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 11\u002F2\u002F20 and 11\u002F29\u002F21 where a sampling plan of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was used to inspect critical features during in-process inspections for which there is no documented rationale for use of this sampling plan. For example, out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ELEOS Tibial Baseplate Component, Size 4 (Part # TB-2204E-01M) Implant Devices, the line profile (curve) for \u003Cstrong>(b)(4)\u003C\u002Fstrong> each were inspected against a specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Similarly, out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ELEOS Collar, 28 Diameter, Round, Porous, HA Treated (Part # HB-2800R-03M) Implant Devices, the diameter for \u003Cstrong>(b)(4)\u003C\u002Fstrong> each was inspected against a specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>b. You reviewed and approved incoming DHRs (Lot #: \u003Cstrong>(b)(4)\u003C\u002Fstrong>) where sampling plans utilized an AQL (acceptable quality limit) of \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> to inspect features during in-process and final inspections for which there are no documented rationales for use of these sampling plans. For example, out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ELEOS Segmental Proximal Femur, Plasma Spray, Left 98 MM (Part # PF-2000L-02M) Implant Devices, the dimensional specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was inspected at an AQL level of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> during final inspection on 1\u002F23\u002F24.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The immediate corrections are to use a checklist to reassess and document rationales for acceptability of the existing AQLs selected for all contract manufactured ELEOS part families from 1\u002F1\u002F21 to 4\u002F1\u002F25 and share the rationales with the contract manufacturers by 11\u002F21\u002F25 and update SCAR 25-01 to require the contract manufacturer to include documented evidence for all inspected dimensions and associated AQL quantities by 5\u002F14\u002F25. As a part of the corrective actions, you plan to update SOP-014 and WI-013-31 (Incoming Inspection Process) to require review of incoming inspection results, consolidation of sampling procedures, set up traceable valid statistical rationales, and confirm AQLs by 7\u002F6\u002F25; update SOP-007 (Design Control) and various design transfer, manufacturing transfer, supplier, and incoming inspection checklists to include instructions for the acceptance of a supplier’s sampling procedure with confirmation of conformance to those procedures during incoming inspection of supplier DHRs by \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and develop \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection requirement checklists for all suppliers with a sampling procedure traceable to a valid statistical rationale based on \u003Cstrong>(b)(4)\u003C\u002Fstrong> by 7\u002F18\u002F25. However, these corrections and\u002For corrective actions only address the need to have a statistically valid rationale for the use of sampling plans which follow AQL and not sampling plans which utilize inspections of select critical features for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices. Therefore, please provide a response on how you plan to address the above deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s ELEOS Limb Salvage System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to submit a medical device Report of Correction or Removal for an action initiated to reduce a risk to health posed by the device or remedy a violation which may present a risk to health, as required by 21 CFR Part 806.10. For example:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>a. Your firm conducted a removal of numerous part numbers and lot numbers of your ELEOS Limb Salvage System due to sterile packaging separation and damaged trays, which can result in extended surgery time or potential patient infection. Your firm sent a Customer Notification for this issue on 6\u002F28\u002F2023. This action meets the definition of a medical device correction or removal initiated to reduce a risk to health or remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\u003C\u002Fp>\u003Cp>b. On or about 10\u002F15\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Male-Female Midsection 40MM, due to taper post misalignment, which can result in extended surgery time or improperly assembled devices leading to future disassociation. Your firm sent a Customer Notification for this issue dated 9\u002F20\u002F2024. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\u003C\u002Fp>\u003Cp>c. On or about 1\u002F22\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Collar Stem, Cemented, Fluted 13MM X 120MM and Collar Stem, Cemented, Fluted 15MM X 120MM due to mislabeling of the devices, which can result in implantation or attempted implantation of an incorrect stem size, potentially extending surgery time or causing the patient to need revision surgery. Your firm sent a Customer Notification for this issue on 12\u002F22\u002F2023. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response, dated 5\u002F14\u002F2025, regarding Observation 5 cannot be determined because we do not have assurance that your firm will make appropriate decisions following 21 CFR 806 in the future, based on your firm’s root cause stating that your firm’s SOP is ambiguous and subjective. Your firm adequately reported by retroactively submitting Reports of Correction or Removal to FDA addressing each of the three issues on 4\u002F25\u002F2025.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 712573” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Len Tokish\u003Cbr>VP of Quality Assurance &amp; Regulatory Affairs\u003Cbr>ltokish@onkossurgical.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPatrick J. Treacy\n\nRecipient Title\n\nPresident and CEO\n\nOnkos Surgical, Inc.\n\n77 E Halsey Rd\n\nParsippany, NJ 07054\n\nUnited States\n\nptreacy@onkossurgical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 712573\nJuly 21, 2025\nDear Mr. Patrick J. Treacy:\nDuring an inspection of your firm located in Parsippany, NJ from February 4, 2025 through April 4, 2025, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer of the ELEOS Limb Salvage System indicated for use in total hip and knee arthroplasty for reduction or relief of pain and\u002For improved hip function in skeletally mature patients with select conditions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Len Tokish, Vice President of Quality Assurance and Regulatory Affairs dated May 15, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including quality requirements, that must be met by suppliers, contractors, and consultants and define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50.\nSpecifically, you failed to adequately implement the “Approved Supplier List” section of your “Supplier, Purchasing and Inspection Controls” procedure (SOP-013; Rev. 0-6; Effective: 4\u002F25\u002F16 - 2\u002F3\u002F25) which requires that you “ensure compliance to ISO 13485” for your Tier 1 suppliers as a “method of control” over approved suppliers. For example, you did not ensure compliance to the process validation requirements (clause 7.5.6) of ISO 13485 (Medical Devices – Quality Management Systems – Requirements for regulatory purposes) for the following three (3) Tier 1 suppliers in that you failed to adequately assess and\u002For document an assessment of the acceptability of their cleaning validations meant to demonstrate that in-process or final cleaning of your ELEOS Implant Devices and Instruments consistently meet your specifications for cleanliness:\na. (b)(4) – Tier (b)(4) Final Cleaner of ELEOS Implant Devices\ni. You approved the (b)(4) cleaning validation test report TR-2771D-01 (Rev. 1-2; Approved: 1\u002F24\u002F19 and 9\u002F10\u002F21) from this supplier despite it failing to define the maximum allowable devices per gallon per run, as required by section 9.2 of the corresponding test protocol TP-2771D-01 (Rev. 2; Approved: 9\u002F10\u002F21) which states “***The main cleaning parameters that can impact the efficacy of the cleaning process include ***Quantity of parts ((b)(4))***.”\nSimilarly, you approved (b)(4) cleaning validation test report TR-2771E-01 (Rev. 1; Approved: 3\u002F18\u002F19) from this supplier despite it failing to document the maximum allowable quantity of (b)(4) and (b)(4) per run, as required by sections 9.3, 9.4, and 9.5 of the corresponding test protocol TP-2771E-01 (Rev. 1; Approved: 8\u002F28\u002F18) which state “***To validate the cleaning process, parts shall be cleaned using (b)(4) over (b)(4) runs***To create a (b)(4) batch of product***Clean what is expected to be a “(b)(4)” load in (b)(4)***A cleaning process should not alter the appearance of parts or cause damage. If applicable, appropriate fixtures to hold the components during cleaning should be included in the study and used in routine production***.”\nii. You failed to adequately assess differences in product design and geometrical configurations of candidate devices for the adoption into device families of existing (b)(4) cleaning validations conducted by this supplier because you did not accurately answer guiding questions contained in your “Assessment of Product Change or New Product Adoption for Cleaning Processes” reports. For example:\n The AC-2772-01 (Rev. 01; Effective: 7\u002F25\u002F19) and AC-277D-01 (Rev. 2; Effective: 2\u002F26\u002F21) reports show that you failed to document rationale to support your answers of “no” to the question posed in section 2 – “In relation to the existing product, does the candidate product have a similar or less complex design?” – despite the candidate devices having 4 grooves, a drive, or a male thread compared to the worst-case and comparison devices, which have none of these features.\n The AC-2772-02 report (Rev. 1; Effective: 3\u002F23\u002F20) shows that you incorrectly answered “no” to the question posed in section 2 – “In relation to the existing product, does the candidate product have fewer\u002Fsmaller or equivalent cannulated portions or lumens?” – when you compared the candidate device (segmental proximal femur, PF-2000L-02M), which has 7 cannulated holes, to the (b)(4) device ((b)(4)) and comparison devices ((b)(4)), which contain no holes.\nb. (b)(4) – Tier 1 (b)(4) Cleaner of ELEOS Implant Devices\nAlthough requested during the inspection, your Vice President of Quality Affairs and Regulatory Affairs was unable to provide documentation that you assessed the adequacy of the cleaning validations conducted in 2009 by this supplier, (b)(4). In reviewing the “Process Validation of***(b)(4) Clean Line” Operational Qualification (OQ) (E118-2116; Rev. 1; Approved: 1\u002F9\u002F09) and Performance Qualification (PQ) (E118-2116; Rev. 1; Approved: 2\u002F3\u002F09), the following deficiencies were observed:\ni. The rationale in the PQ report to accept deviations from the nominal operating range of (b)(4)°F ((b)(4), and (b)(4)°F) because OQ data showed that the process monitoring, total organic carbon (TOC), and gravimetric produced acceptable results at worst-case conditions for temperatures as low as (b)(4)°F and control charts indicated a lower control limit of (b)(4)°F (Deviation 3) does not take into account the vast differences in sample sizes ((b)(4) vs. (b)(4)) and acceptance criterion (Ppk (b)(4) vs. Ppk (b)(4)) between PQ and OQ for the same tests (TOC and gravimetric analysis) such that passing results for parameters established during OQ are not transferrable to PQ.\nii. This supplier failed to document rationale in the OQ and PQ reports for why it was acceptable to convert all negative values measured for the corrected “mass recovered from gravimetric (b)(4) and corrected “mass recovered from (b)(4) to 0.00 mg in the “Gravimetric Extraction Summary” table during gravimetric testing, thereby passing the acceptance criteria of (b)(4) mg\u002Fcm2 ((b)(4)). For example, during OQ, an (b)(4) value as high as -1.59 mg for “Hip – 4” was converted to 0.00 mg without an explanation that accounts for the possibility of testing errors, inadequate test methodology (e.g., lack of sensitivity of testing methods), and uncalibrated state of measuring equipment.\nc. (b)(4) – (b)(4) Cleaner of ELEOS Implant Devices & (b)(4) Cleaner of ELEOS Instruments\nYou approved the adoption of new products into this supplier’s existing (b)(4) cleaning validations titled “(b)(4) Cleaning Equipment & Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) and “Zenith Final Ultrasonic Cleaning Equipment & Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) per your Cleaning, Assembly, Packaging and Sterility (CAPS) Checklists for Project # 16-001 (Approved 10\u002F2\u002F24) and Project # 16-003 (Approved 4\u002F19\u002F24) referencing memo “(b)(4) Cleaning” (2\u002F14\u002F19) and results of a 3rd party audit conducted 2\u002F23\u002F18 despite the following deficiencies:\ni. The OQ and PQ protocols failed to require documentation of the load configurations for all work orders in that the Vice President of Quality Affairs and Regulatory Affairs was not able to determine if devices were put in a (b)(4) or broken up into (b)(4).\nii. The PQ protocol failed to include documentation of valid statistical rationale for cytotoxicity, endotoxin, and\u002For particulate testing. For example, the quantity tested per work order (66672, 66921, 66922) for cytotoxicity and endotoxin was (b)(4) and (b)(4) respectively and the quantity tested per work order (66675, 66919, 66920) for cytotoxicity, endotoxin, and particulate was (b)(4) and (b)(4), respectively.\nWe reviewed your firm’s response and concluded that it is not adequate. The immediate correction is to impose heightened controls at each supplier commensurate with risk until new worst-case cleaning validations can be completed that addresses each of the observed deficiencies for (b)(4) by 1\u002F15\u002F26, (b)(4) (target date not provided), and (b)(4) by 3\u002F1\u002F26 at the latest.\nFor (b)(4), an assessment of worst-case part justification by family was completed to establish new limits placed on (b)(4), and (b)(4). You plan to add this new loading criteria to the final DHR review by 7\u002F15\u002F25. In addition, you plan to require an update to (b)(4) internal procedure to include predicate cleaning validation review by 7\u002F15\u002F25. Based on the results of the new cleaning validation, you plan to revise top level procedures by (b)(4).\nFor (b)(4), an assessment of worst-case part justification was conducted and monitoring was put in place to control product release by assessing endotoxicity and cytotoxicity on a (b)(4) basis. In addition, you plan to require an update to this supplier’s internal procedures to improve notification of triggers to their customers by 7\u002F1\u002F25.\nFor (b)(4), you plan to conduct an assessment for worst-case part challenge per part family by (b)(4). For all instruments, interim clean line controls were implemented to require shipment of instruments to your firm and analyses of those instruments, which includes worst-case part and part family assessments prior to adoption into your clean-line part family. All parts successfully assessed will then be cleaned using your validated clean line prior to release for commercial distribution. All implants will continue to be shipped to (b)(4) for (b)(4) cleaning and will fall under controls established for therein.\nCorrective actions include updating your supplier control and design control procedures to establish minimum requirements for cleaning validations of implants and instruments, including defining key product attributes to consider when forming product families and what considerations trigger a new worst-case within a product family or new product cleaning family; creation of a procedure for part families and worst-case parts per family which defines and evaluates implant and instrument cleaning families to facilitate consistent assessment of device cleaning families across products; determination and justification of minimum sample size and attributes ((b)(4)) for validations; development of a cleaning validation checklist and modification of a supplier audit checklist that captures the aforementioned worst-case part determination, sample sizes, and minimum attributes that will be used during supplier assessment as part of design transfer and new supplier onboarding, manufacturing transfer, and supplier audit; and periodic review of validations on a scheduled interval against new standards and requirements by 6\u002F15\u002F25.\nHowever, no target date was provided for the new cleaning validation planned for (b)(4). Therefore, please provide a response regarding how you plan to address this deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, you failed to implement your Post Market Surveillance procedure (QP-18-004; Rev. 3; Effective: 6\u002F30\u002F22) which requires opening a CAPA when the (b)(4) analysis of infection complaints “***is more than (b)(4) above the literature rate or (b)(4) are above the literature rate***” for a given procedure type. For example, you did not initiate CAPAs when the (b)(4) analysis for infection complaints exceeded the rates of (b)(4)% for the distal femur ((b)(4)); (b)(4)% for proximal femur ((b)(4) and (b)(4)); and (b)(4)% for total femur ((b)(4) and (b)(4)) established in the journal article by Henderson et. al “Failure Mode Classification for Tumor Endoprostheses: Retrospective Review of Five Institutions and a Literature Review” (Journal Bone and Joint Surgery 2011) by (b)(4).\nThe adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. Under CAPA 24-011 which was initiated on 9\u002F11\u002F24 to create a more robust methodology for trending and analyzing infection related complaints, you conducted a revised retrospective assessment of (b)(4) infection rates from (b)(4) to (b)(4) (TM-25-0002; Rev. B; Approved 5\u002F14\u002F25) based on additional literature data to support updated baseline infection rates by procedure type. As a part of the corrective action, you plan to create new work instructions with requirements to perform (b)(4) trend reporting for infections and (b)(4) or (b)(4) trend reports for all other postmarket surveillance key performance indicators (KPIs); revise management review presentation slides and quality planning, postmarket surveillance, complaint handling, and CAPA procedures; and provide training on the new procedures. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n3. Failure to adequately establish and maintain procedures for validating the device design with regards to risk analysis, as required by 21 CFR 820.30(g).\nSpecifically, you failed to implement section 5.9 of your “Risk Management Process” procedure (SOP-008; Rev. 4-5; Effective: 3\u002F22\u002F23 - 1\u002F17\u002F25) which requires postmarket re-evaluation of risk management for a medical device as well as monitoring of postmarket information “***for assurance that no unacceptable or previously unrecognized failure modes occur. In the event of such an occurrence the potential that the residual risk or its acceptability has changed and the impact on the previously implemented risk control measures shall be evaluated***.” For example, you failed to utilize the real rate of occurrence for loosening in complaints PCR 11272023-1 ((b)(4)), PCR 05132024-1 ((b)(4)), and PCR 10172024-1 ((b)(4)) calculated at 3.27%, 0.149%, and 3.1%, respectively, to evaluate the need to update the occurrence rating in the corresponding ELEOS Stem Implant Risk Table (Project # 16-001\u002F16-003; Rev. E; Approved: 4\u002F1\u002F19), which remains unchanged at (b)(4)% through (b)(4)% since April 1, 2019.\nAn update to the postmarket rate of occurrence changes the failure mode from an acceptable risk to a conditionally acceptable risk, thereby requiring an evaluation for the need for additional risk controls and assessment for the acceptability of the residual risk as required under sections 5.6 and 5.7 of SOP-008.\nThe adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. The immediate correction is to evaluate literature, sources, historical data, and\u002For engineering estimates against postmarket data and update the occurrence rates for the hazardous situations associated with the ELEOS Limb Salvage system by (b)(4) followed by a revision of the corresponding risk tables by (b)(4). As a part of the corrective action, you plan to revise SOP-008 to ensure that the methods used to create and maintain risk assessment tables are well-defined and create work instructions for conducting risk assessments utilizing postmarket information by (b)(4). Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n4. Failure to establish and maintain procedures for identifying valid statistical techniques required for establishing, controlling, and verifying the acceptability of process capability and product characteristics, as required by 21 CFR 820.250(a).\nSpecifically, you failed to implement section 1.1 of your “Sample Size and Statistical Techniques” procedure (SOP-014; Rev. 2-4; Effective: 8\u002F16\u002F18 - 3\u002F22\u002F23) which “***identifies valid statistical techniques that are used to establish, control and verify the acceptability of process capability and product characteristics***” pertaining to “***inspections and other analyses of objective data***” of ELEOS Implant Devices received from (b)(4). during incoming inspections. For example, your Vice President of Quality Affairs and Regulatory Affairs acknowledged that the sampling plans of the (b)(4) sampled incoming device history records (DHRs) from this supplier were not traceable to a documented valid statistical rationale.\na. You reviewed and approved incoming DHRs for Lot # (b)(4) and Lot # (b)(4) on 11\u002F2\u002F20 and 11\u002F29\u002F21 where a sampling plan of (b)(4) was used to inspect critical features during in-process inspections for which there is no documented rationale for use of this sampling plan. For example, out of (b)(4) ELEOS Tibial Baseplate Component, Size 4 (Part # TB-2204E-01M) Implant Devices, the line profile (curve) for (b)(4) each were inspected against a specification of (b)(4) at (b)(4) for Lot # (b)(4). Similarly, out of (b)(4) ELEOS Collar, 28 Diameter, Round, Porous, HA Treated (Part # HB-2800R-03M) Implant Devices, the diameter for (b)(4) each was inspected against a specification of (b)(4) at (b)(4) for Lot # (b)(4).\nb. You reviewed and approved incoming DHRs (Lot #: (b)(4)) where sampling plans utilized an AQL (acceptable quality limit) of (b)(4) or (b)(4) to inspect features during in-process and final inspections for which there are no documented rationales for use of these sampling plans. For example, out of (b)(4) ELEOS Segmental Proximal Femur, Plasma Spray, Left 98 MM (Part # PF-2000L-02M) Implant Devices, the dimensional specification of (b)(4) was inspected at an AQL level of (b)(4) for Lot # (b)(4) during final inspection on 1\u002F23\u002F24.\nWe reviewed your firm’s response and concluded that it is not adequate. The immediate corrections are to use a checklist to reassess and document rationales for acceptability of the existing AQLs selected for all contract manufactured ELEOS part families from 1\u002F1\u002F21 to 4\u002F1\u002F25 and share the rationales with the contract manufacturers by 11\u002F21\u002F25 and update SCAR 25-01 to require the contract manufacturer to include documented evidence for all inspected dimensions and associated AQL quantities by 5\u002F14\u002F25. As a part of the corrective actions, you plan to update SOP-014 and WI-013-31 (Incoming Inspection Process) to require review of incoming inspection results, consolidation of sampling procedures, set up traceable valid statistical rationales, and confirm AQLs by 7\u002F6\u002F25; update SOP-007 (Design Control) and various design transfer, manufacturing transfer, supplier, and incoming inspection checklists to include instructions for the acceptance of a supplier’s sampling procedure with confirmation of conformance to those procedures during incoming inspection of supplier DHRs by (b)(4); and develop (b)(4) inspection requirement checklists for all suppliers with a sampling procedure traceable to a valid statistical rationale based on (b)(4) by 7\u002F18\u002F25. However, these corrections and\u002For corrective actions only address the need to have a statistically valid rationale for the use of sampling plans which follow AQL and not sampling plans which utilize inspections of select critical features for the (b)(4) devices. Therefore, please provide a response on how you plan to address the above deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\nCorrections and Removals Violation(s)\nOur inspection also revealed that your firm’s ELEOS Limb Salvage System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\n5. Failure to submit a medical device Report of Correction or Removal for an action initiated to reduce a risk to health posed by the device or remedy a violation which may present a risk to health, as required by 21 CFR Part 806.10. For example:\na. Your firm conducted a removal of numerous part numbers and lot numbers of your ELEOS Limb Salvage System due to sterile packaging separation and damaged trays, which can result in extended surgery time or potential patient infection. Your firm sent a Customer Notification for this issue on 6\u002F28\u002F2023. This action meets the definition of a medical device correction or removal initiated to reduce a risk to health or remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\nb. On or about 10\u002F15\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Male-Female Midsection 40MM, due to taper post misalignment, which can result in extended surgery time or improperly assembled devices leading to future disassociation. Your firm sent a Customer Notification for this issue dated 9\u002F20\u002F2024. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\nc. On or about 1\u002F22\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Collar Stem, Cemented, Fluted 13MM X 120MM and Collar Stem, Cemented, Fluted 15MM X 120MM due to mislabeling of the devices, which can result in implantation or attempted implantation of an incorrect stem size, potentially extending surgery time or causing the patient to need revision surgery. Your firm sent a Customer Notification for this issue on 12\u002F22\u002F2023. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\nThe adequacy of your firm’s response, dated 5\u002F14\u002F2025, regarding Observation 5 cannot be determined because we do not have assurance that your firm will make appropriate decisions following 21 CFR 806 in the future, based on your firm’s root cause stating that your firm’s SOP is ambiguous and subjective. Your firm adequately reported by retroactively submitting Reports of Correction or Removal to FDA addressing each of the three issues on 4\u002F25\u002F2025.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 712573” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Len Tokish\nVP of Quality Assurance & Regulatory Affairs\nltokish@onkossurgical.com","Onkos Surgical, Inc.","onkos-surgical-inc-712573-07212025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fonkos-surgical-inc-712573-07212025","2026-10-26T08:09:38.140644+00:00","2025-07-29","712573","Patrick J. Treacy","2026-08-19T16:32:45.913+00:00","2025-07-21",{"id":71,"raw":72,"subject":77,"body_html":78,"body_text":79,"firm_name":80,"letter_id":81,"created_at":82,"fei_number":19,"letter_url":83,"updated_at":84,"action_type":22,"case_status":23,"posted_date":85,"marcs_cms_no":86,"product_type":87,"closeout_date":19,"issuing_office":76,"recipient_name":88,"body_fetched_at":89,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":90,"medical_device_id":19,"response_letter_date":19},3593,[73,74,75,76,77,13,13,13],"\u003Ctime datetime=\"2021-01-05T15:00:00Z\">01\u002F05\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-04T05:00:00Z\">01\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcocos-holistic-specialties-apothecary-612001-01042021\">Coco&#039;s Holistic Specialties &amp; Apothecary\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Janine Havins\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Coco's Holistic Specialties &amp; Apothecary\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:cocosholisticspecialties.etsy@gmail.com\"> cocosholisticspecialties.etsy@gmail.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>WARNING LETTER\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;January 4, 2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>RE:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This is to advise you that the United States Food and Drug Administration (FDA) [and the Federal Trade Commission (FTC)] reviewed your website at the Internet address https:\u002F\u002Fcocosholisticspecialties.org\u002F&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>on November 19\u003Csup>th\u003C\u002Fsup>, 2020, and December 17, 2020, respectively. We also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002FKaliLengua and https:\u002F\u002Ftwitter.com\u002FCocoEtsy,\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>&nbsp;where you direct consumers to your website, https:\u002F\u002Fcocosholisticspecialties.org\u002F&nbsp;to purchase your products. &nbsp;The FDA has observed that your website offers 4-Thieves Florida Tea Concentrate and 4-Thieves Florida Tea Powder for sale in the United States and that this product is intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[1]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> in people.&nbsp; Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[2]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> &nbsp;In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[3]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> &nbsp;Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. &nbsp;As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. &nbsp;We request that you take immediate action to cease the sale of such unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Some examples of the claims on your websites that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“[A]ntiviral, ongoing clinical research on effectiveness against COVID-19” [from your website, https:\u002F\u002Fcocosholisticspecialties.org\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“January I decided to put aside her [\u003Ci>sic\u003C\u002Fi>] upwards of 20 different holistic plant-based product lines to focus on binge researching herbs from past pandemics, why they worked, what the similarities there are to CV-19 . . .&nbsp; In January this year when I 1\u003Csup>st\u003C\u002Fsup> heard of what later transpired into the Novel Coronavirus Pandemic, had binge-researched pandemics of the past, and what had been used to remedy them at those times . . . there were enough similarities between the transhuman variations . . . that I was so intrinsically inclined to acquire the herbs I researched for the original Marseilles France 4-Thieves recipe . . . I next binge-researched what antiviral herbs I could augment in to make it effective against Covid-19 . . . I had taken out the 2 herbs that \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>made the original for external use only, cause I intended to make tea pills to inoculate CV-19, exchanging those with 6 herbs that specifically kill viruses...!” \u003Cspan>[from your website, https:\u002F\u002Fcocosholisticspecialties.org\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>”\u003C\u002Fspan>\u003Cspan>\u003Cspan>4-Thieves Florida Tea Concentrate is an anti-COVID herbal inoculation, that is 100% plant-based.”\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan> [from the “About” section of your Facebook account, &nbsp;&nbsp;[From your social media website in the “About” section, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>https:\u002F\u002Fwww.facebook.com\u002FKaliLengua\u002F]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“[W]anted to share my COVID story . . . [t]here were 8 women that allowed me to treat them for covid-19(-like symptoms) as well as using on myself as a preventative . . . [t]he only thing I’ve been using this whole time, since I finished my 1st batch the 2nd week of February, my 4-Thieves Florida Tea Concentrate . . . The herbal prophylactic inoculation I made against Coronavirus is safe &amp; effective for people of all ages &amp; health conditions.”&nbsp; [From an August 12, 2020 post on your social media website https:\u002F\u002Fwww.facebook.com\u002FKaliLengua].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“I had formulated in January of this year from my binge-researching pandemics of the past &amp; found that 4-Thieves was the only thing effective against the Black Plague of the dark ages(14-1700s). It was found to be a bacterial infection, &amp; 2 ingredients in the original recipe created in Marseilles England by the mother of one of the 4 thieves, made the recipe for external use only &amp; not effective against viruses. So listening to my intuition &amp; knowledge I further binge-researched what antiviral herb I could replace those 2 with to make it effective against COVID-19. After having run my own clinical trials resulting in proof of the efficacy of my anti-viral variation of this herbal inoculation, I aptly named it 4-Thieves Florida Tea, &amp; I sell it as a concentrate.” [from a June 15, 2020 post on your social media website \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>https:\u002F\u002Fwww.facebook.com\u002FKaliLengua\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“This is me singing . . . because it waa [\u003Ci>sic\u003C\u002Fi>] the best way I could think of to show my health 10 days after the beginning of my exposure to COVID-19 that I still [am] healthy as a horse, due to my antiviral herbal inoculation.” [from a September 21, 2020 tweet from your social website \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>https:\u002F\u002Ftwitter.com\u002FCocoEtsy\u003Cspan>].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You should take immediate action to address the violations cited in this letter.&nbsp; This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations.&nbsp; It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. &nbsp;We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. &nbsp;\u003Cb>Within 48 hours, please send an email to \u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cb>\u003Cspan>\u003Cspan>COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003Cb> \u003C\u002Fb>\u003Cspan>\u003Cspan>describing the specific steps you have taken to address these violations. &nbsp;Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation.&nbsp; Failure to immediately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19.&nbsp; Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act.&nbsp; This list can be found at \u003C\u002Fspan>\u003Cspan>http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. &nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and such actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken appropriate corrective action.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. &nbsp;If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. &nbsp;We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please direct any inquiries to FDA at \u003C\u002Fspan>\u003Cspan>COVID-19-Task-Force-CDER@fda.hhs.gov.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>In addition, it is unlawful under the FTC Act, 15 U.S.C. 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made.&nbsp; For COVID-19, no such study is currently known to exist for the product identified above.&nbsp; Thus, any coronavirus-related prevention or treatment claims regarding such product are not supported by competent and reliable scientific evidence.&nbsp; You must immediately cease making all such claims.&nbsp; Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. &nbsp;Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov describing the specific actions you have taken to address the FTC’s concerns. &nbsp;If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at \u003Cspan>202-326-3088\u003C\u002Fspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>&nbsp;&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Donald D. Ashley\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance&nbsp;&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Drug Evaluation and Research&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Food and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Serena Viswanathan\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Acting Associate Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Division of Advertising Practices&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Federal Trade Commission&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cdiv>&nbsp;\n\u003Chr>\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[1]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[2]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan> Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists.&nbsp; Jan. 31, 2020.&nbsp; (Accessible at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx). The declaration has been renewed for an additional 90 days three times.&nbsp; The most recent renewal went into effect on October 23, 2020.&nbsp; Secretary of Health and Human Services Alex M. Azar II, Renewal of Determination that a Public Health Emergency Exists. October 2, 2020. (Accessible at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fcovid19-2Oct2020.aspx).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[3]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan> President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19).&nbsp; Mar. 13, 2020.&nbsp; (Accessible at https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJanine Havins\n\nCoco's Holistic Specialties & Apothecary\n\nUnited States\n\ncocosholisticspecialties.etsy@gmail.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nDate: January 4, 2021\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) [and the Federal Trade Commission (FTC)] reviewed your website at the Internet address https:\u002F\u002Fcocosholisticspecialties.org\u002F on November 19th, 2020, and December 17, 2020, respectively. We also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002FKaliLengua and https:\u002F\u002Ftwitter.com\u002FCocoEtsy, where you direct consumers to your website, https:\u002F\u002Fcocosholisticspecialties.org\u002F to purchase your products. The FDA has observed that your website offers 4-Thieves Florida Tea Concentrate and 4-Thieves Florida Tea Powder for sale in the United States and that this product is intended to mitigate, prevent, treat, diagnose, or cure COVID-19[1] in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.[2] In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.[3] Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your websites that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“[A]ntiviral, ongoing clinical research on effectiveness against COVID-19” [from your website, https:\u002F\u002Fcocosholisticspecialties.org\u002F]\n\n“January I decided to put aside her [sic] upwards of 20 different holistic plant-based product lines to focus on binge researching herbs from past pandemics, why they worked, what the similarities there are to CV-19 . . . In January this year when I 1st heard of what later transpired into the Novel Coronavirus Pandemic, had binge-researched pandemics of the past, and what had been used to remedy them at those times . . . there were enough similarities between the transhuman variations . . . that I was so intrinsically inclined to acquire the herbs I researched for the original Marseilles France 4-Thieves recipe . . . I next binge-researched what antiviral herbs I could augment in to make it effective against Covid-19 . . . I had taken out the 2 herbs that made the original for external use only, cause I intended to make tea pills to inoculate CV-19, exchanging those with 6 herbs that specifically kill viruses...!” [from your website, https:\u002F\u002Fcocosholisticspecialties.org\u002F].\n\n”4-Thieves Florida Tea Concentrate is an anti-COVID herbal inoculation, that is 100% plant-based.” [from the “About” section of your Facebook account, [From your social media website in the “About” section, https:\u002F\u002Fwww.facebook.com\u002FKaliLengua\u002F].\n\n“[W]anted to share my COVID story . . . [t]here were 8 women that allowed me to treat them for covid-19(-like symptoms) as well as using on myself as a preventative . . . [t]he only thing I’ve been using this whole time, since I finished my 1st batch the 2nd week of February, my 4-Thieves Florida Tea Concentrate . . . The herbal prophylactic inoculation I made against Coronavirus is safe & effective for people of all ages & health conditions.” [From an August 12, 2020 post on your social media website https:\u002F\u002Fwww.facebook.com\u002FKaliLengua].\n\n“I had formulated in January of this year from my binge-researching pandemics of the past & found that 4-Thieves was the only thing effective against the Black Plague of the dark ages(14-1700s). It was found to be a bacterial infection, & 2 ingredients in the original recipe created in Marseilles England by the mother of one of the 4 thieves, made the recipe for external use only & not effective against viruses. So listening to my intuition & knowledge I further binge-researched what antiviral herb I could replace those 2 with to make it effective against COVID-19. After having run my own clinical trials resulting in proof of the efficacy of my anti-viral variation of this herbal inoculation, I aptly named it 4-Thieves Florida Tea, & I sell it as a concentrate.” [from a June 15, 2020 post on your social media website https:\u002F\u002Fwww.facebook.com\u002FKaliLengua].\n\n“This is me singing . . . because it waa [sic] the best way I could think of to show my health 10 days after the beginning of my exposure to COVID-19 that I still [am] healthy as a horse, due to my antiviral herbal inoculation.” [from a September 21, 2020 tweet from your social website https:\u002F\u002Ftwitter.com\u002FCocoEtsy].\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to immediately address this matter may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and such actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken appropriate corrective action.\n\nIf you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nIn addition, it is unlawful under the FTC Act, 15 U.S.C. 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the product identified above. Thus, any coronavirus-related prevention or treatment claims regarding such product are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov describing the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nActing Associate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n[1] As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n[2] Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists. Jan. 31, 2020. (Accessible at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx). The declaration has been renewed for an additional 90 days three times. The most recent renewal went into effect on October 23, 2020. Secretary of Health and Human Services Alex M. Azar II, Renewal of Determination that a Public Health Emergency Exists. October 2, 2020. (Accessible at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fcovid19-2Oct2020.aspx).\n\n[3] President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19). Mar. 13, 2020. (Accessible at https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F).","Coco's Holistic Specialties & Apothecary","cocos-holistic-specialties-apothecary-612001-01042021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcocos-holistic-specialties-apothecary-612001-01042021","2026-10-26T08:08:16.623324+00:00","2021-01-05","612001","Drugs","Janine Havins","2026-08-20T03:28:02.866+00:00","2021-01-04",4,{"510k":93,"classification":94,"enforcement":95,"event":96,"event_backfill":97,"pma":98,"warning_letter":99},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]